Leonardo Gil-Santana, MD

Inviting to join the Global Oncology community, get access to Education resources and online classes. Join the special session of Global Oncology myconnection.asco.org/discussion/glo… @nnadiagee @JCOGO_ASCO @ASCO @venkymd @Amolpatel_dr @leogilsan @LauBernalOnc @AmalAljuhani27 @GevTamamyan

ICYMI, @ASCO abstracts release next week! Here's my top 10 lists for: 👉 Lung Cancer Abstracts to watch #lcsm 👉 Devp. therapeutics Abstracts to watch 👉 #AI in oncology Abstracts to watch and ofcourse, the #plenaries 2 weeks to go for #ASCO26! @OncoAlert @oncodaily

🚨 GBOT ALERTA – Estadiamento mediastinal no CPCNP Diretriz do Grupo Brasileiro de Oncologia Torácica (GBOT): 📌 TC e PET-CT têm acurácia limitada para N2/N3 • sROC: 0,73 e 0,87 ⚠️ PET-CT pode gerar falso-positivos em áreas endêmicas para granulomatoses (ex: TB) ✅ EBUS + EUS = maior acurácia diagnóstica • sROC: 0,99 • Performance comparável à mediastinoscopia 🧠 Pontos-chave: • Imagem isolada NÃO basta • Confirmação tecidual é essencial • EBUS/EUS deve ser primeira linha • Mediastinoscopia fica reservada para casos selecionados 🎯 Estadiamento preciso evita cirurgias desnecessárias e acelera o tratamento. #NSCLC #EBUS #EUS #PETCT #OncologiaTorácica #GBOTjovem @SBOC_Oncologia @IASLC linkinghub.elsevier.com/retrieve/pii/S…

🎯🔥⚽️the most funky, friendly, fashioned social event is coming again!! 💪💪 @ASCO @ASCOPres 🚀 The World #ASCO26 football Cup! @DrChoueiri @FAndreMD 📆 Saturday May 30th (6.00-10.00PM) Registration is open Contact: cdanicas@gmail.com 🙌🙌Brasil, Argentina, Colombia,Peru and USA are confirmed🏃‍♂️🏃‍♂️ The latest versions were a lot of fun. 😎 Don't miss it and sign up!🔥 With a rock stars @DrChoueiri !! @OncoAlert @aaoncoclinica @SoaresAndrey @myESMO @raymanneh @GuardConsortium @DrFelixGuerrero

@chulkimMD 👏👏👏

May is Thymic Malignancy Awareness Month! Join us for a FREE webinar series covering the latest in thymic epithelial tumors. Register: itmig.org/tmam/ 📋 May 20 — Clinical Guidelines Updates 🏥 May 20 — Multidisciplinary Care: Surgery to QoL 🧬 May 22 — Clinical Trials & Emerging Therapies 🔬 May 28 — Challenges in Thymic Tumor Pathology 🌍 Jun 9 — Treatment Access Worldwide @Itmig_society

O GBOT realiza mais um webinar científico no dia 12/05 com o tema “Como a imunoterapia chega ao SUS: do desenvolvimento clínico à transferência de tecnologia e decisão da CONITEC”, com programação das 19h30 às 21h. A abertura será conduzida pelo moderador Vladmir Lima (SP), oncologista torácico do A.C.Camargo Cancer Center e presidente do Grupo Brasileiro de Oncologia Torácica. O evento contará com a participação de Tiago Rocca (SP), especialista em Direito da Saúde, com atuação em gestão e desenvolvimento de parcerias estratégicas, e de Cecília Lameirinhas Longo (RJ), oncologista clínica e pesquisadora da Rede Américas. As inscrições estão disponíveis através do link: gbot.med.br/login-membros/… #webinar #oncologia #imunoterapia #sus #gbot

⚡Rapid oral highlights in metastatic lung cancer at #ASCO26 A visual snapshot of key rapid oral abstracts spanning EGFR-targeted therapy, bispecifics, ADCs, KRAS/ALK resistance, and other next-generation strategies in advanced NSCLC👀🫁 #LCSM @OncoAlert @EGFRResisters @Larvol

✨Rapid oral highlights in loco-regional lung cancer at #ASCO26 A quick visual overview of important abstracts across surgery, perioperative therapy, SCLC translational studies, MRD, TME, and recurrence risk 🫁📊 @OncoAlert #LCSM @Larvol

Dr. Tina Cascone with an insightful discussion on the MATISSE trial at #AACR26 plenary session. Outlines the current state of neoadjuvant and perioperative immunotherapy for NSCLC. A multitude of options now available demonstrating improved pCR, EFS, and OS fof resectable NSCLC.

#ASCO abstract titles just released. Two lung cancer abstracts during plenary this year! • LIBRETTO-432: Adjuvant #selpercatinib in stage IB–IIIA RET+ NSCLC by Dr. Jonathan Goldman • Advanced squamous NSCLC: #ivonescimab + chemo vs #tislelizumab + chemo by Dr. Shun Lu

@DrYujiUehara @ASCO @ASCOTECAG Congratulations!!

Honored to share that I have been selected to serve as a member of the ASCO Trainee & Early Career Advisory Group (TECAG). Look forward to contributing to ASCO’s initiatives and supporting the professional development of early career members. @ASCO @ASCOTECAG #LCSM

RevMed with huge news for pancreatic cancer (daraxonrasib). The headline is hard to ignore 👀 • Median OS 13.2 vs 6.7 months • HR ~0.4 📉 • Activity across KRAS variants (not just G12C) • Manageable safety If that signal is real, this isn’t incremental. It changes how we think about KRAS. But—caveat applies ⚠️ This is a press release! PR as a rule is rosier than real data. Still… an OS HR like that gets your attention. Feels like we may be moving from mutation-specific inhibition → broader KRAS control. That’s the difference between niche utility and something that touches CRC, pancreas, lung… everything we see. Now we wait for the data behind the headline. @TheGutOncLab @OncoAlert @Onco_Nexus ir.revmed.com/news-releases/…

@SamsungBrasil O final perfeito é Feito com Galaxy

📸 Uma história em fotos está prestes a ser contada e você vai criar o final! Passo 1 - Confira as três imagens desse post; Passo 2 - Agora, poste a quarta foto para encerrar a história junto com a frase “o final perfeito é Feito com Galaxy”; Passo 3 - Fique atento à sua DM e ao perfil SamsungBrasil! As fotos mais criativas vão ganhar um Galaxy S26 Ultra.

ITMIG 2026 Abstract Submission is now OPEN! Join us in São Paulo, Nov 12–14, 2026, and share your work in thymic malignancies with a global, multidisciplinary community. Basic, translational, and clinical research all welcome. Submit here: bit.ly/4e40ZMg

Amazing to see the dramatic improvements pushing the PFS curves up and thereby offering extended life and more hope for our patients- a diagnosis of advanced NSCLC was like looking down a precipice in 2002 Revised the image to show that all this is thanks to a lot of passionate weightlifters: Basic/translational scientists Industry friends Clinical trialists/trial teams Reg agencies Patient advocates etc lifting that PFS curve upwards day-by-day But we need to push still more to be able to have our patients rest on and enjoy a comfortable survival plateau! #lcsm

Honored to share that our work has been accepted for presentation at #ASCO2026. A true team effort alongside outstanding mentors and colleagues, highlighting the strength of Brazilian oncology research on the global stage. @GBOT_Alerta @LACOG_group @ESaldanhaMD @ClaudioVladmir

@GuiNaderMarta @myESMO @DFCI_BreastOnc @TeresaSAmaral @E_de_Azambuja @AlbertoPuccini @chierrocarbo @EdmondMKwan @ElisaAgostinett @lateuwen @Lawson_Eng @DrShanilaAhmed @VAfrasanie Congrats 👏🏽👏🏽👏🏽

Honored to have been accepted into the @myESMO Leadership Programme 2025–2026 Grateful for the opportunity to learn and grow alongside colleagues from around the world esmo.org/career-develop… @DFCI_BreastOnc

@GuiNaderMarta @myESMO @DFCI_BreastOnc @Rodrosb @E_de_Azambuja @matteolambe Congratulations!

Honored to join the @myESMO Young Oncologists Committee! Grateful for the opportunity to contribute and help support the next generation of YOCs through education, mentorship, and global collaboration. Excited for what’s ahead!

@oncodaily @myESMO @OncoAlert @Larvol Thank you to share.

@leogilsan @myESMO @OncoAlert @Larvol We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing oncodaily.com/blog/leonardo-…

Presenting now our real-world data on PIK3CA-mutated mCRC from Brazil 🇧🇷 at #ESMOGI2025! #ColorectalCancer #PIK3CA #OncologyResearch #GIoncology @myESMO @OncoAlert @oncodaily @Larvol